28 Adjunct and Integrative Cancer Treatments Backed by Medical Literature (2026)

Updated June 2026 · Evidence-Ranked Edition
This article has been reorganised to rank all 28 integrative cancer interventions by the quality and quantity of available evidence — from randomised controlled trial data down to preclinical laboratory findings. Use this as a structured reference, not a treatment guide. Always consult a qualified healthcare professional before initiating any therapy.

⚠️ Medical Disclaimer: This content is for educational purposes only. Nothing in this article should be used as the basis for initiating, modifying, or discontinuing any cancer treatment without guidance from your treating oncologist or physician. The interventions described here are not approved cancer treatments unless explicitly stated.

Diverse cancer hallmarks targeted by repurposed non-oncology drugs. Source: Nature 2024

Introduction

Most mainstream guides to "alternative cancer treatments" — including the widely cited Mayo Clinic overview — focus primarily on supportive care: acupuncture, massage, meditation. These are integrative therapies that complement standard oncology, not strategies with direct anti-tumour evidence.

This article takes a different approach. It catalogues 28 interventions — from approved immunotherapy (BCG) to repurposed drugs, lifestyle strategies, and experimental compounds — and ranks them by the quality and volume of available evidence. The goal is to give patients, caregivers, and clinicians a structured reference they can actually use.

Think of cancer therapy as a chessboard: no single piece wins the game alone. Victory comes from coordinating pieces to create strategic advantage. The strongest interventions below should be considered first, as part of a comprehensive plan developed with a qualified integrative or conventional oncologist.

📌 Access note: Effective modern cancer therapies (immunotherapy, targeted agents) remain unevenly distributed globally. Repurposed drugs offer lower-cost options worth investigating — particularly in low- and middle-income countries where treatment infrastructure lags behind clinical need (WEF 2024, WHO 2024).

Methodology: Evidence Tier Framework

Evidence quality hierarchy. Meta-analyses of RCTs occupy the apex; preclinical studies form the base.

Interventions are organised into four evidence tiers:

Tier	Evidence Quality	Examples
Tier 1 — Strong	Meta-analyses of RCTs; approved clinical indications; landmark guideline-changing trials	BCG, Aspirin (PIK3CA-mutant CRC), Exercise, Metformin, Statins, Cimetidine (CRC)
Tier 2 — Moderate	Individual RCTs; systematic reviews with clinical trial data; prospective cohorts	Propranolol, Vitamin D3, Omega-3, Vitamin C (IV), Hyperthermia, Aspirin (other cancers), Melatonin
Tier 3 — Emerging	Observational studies, retrospective analyses, small clinical series, case series with mechanistic support	Ivermectin, Benzimidazoles, Curcumin, Green Tea (EGCG), Berberine, Disulfiram, Itraconazole, Sildenafil/PDE5i, Glucose/Keto, Methylene Blue
Tier 4 — Experimental	Primarily preclinical (cell/animal); limited or no human data; case reports only	DMSO, Ashwagandha, HBOT, Gerson Therapy, Hydralazine (GBM), Stress/Sleep/Sunshine

Quick Reference: All 28 Interventions at a Glance

#	Intervention	Tier	Best Evidence Context	Human Trials?
1	BCG Immunotherapy	Tier 1	Bladder cancer (non-muscle invasive)	Yes — Approved
2	Aspirin + COX-2 Inhibitors	Tier 1	PIK3CA-mutant CRC (ALASCCA RCT, NEJM 2025)	Yes — RCT
3	Exercise	Tier 1	Multi-cancer survival improvement	Yes — Meta-analyses
4	Metformin	Tier 1	Multiple cancers; metabolic suppression	Yes — RCTs ongoing
5	Statins	Tier 1	Colorectal, breast, prostate cancers	Yes — Meta-analyses
6	Cimetidine (H2 Blockers)	Tier 1	Colorectal cancer (Cochrane meta-analysis)	Yes — 6 RCTs pooled
7	Propranolol	Tier 2	Perioperative use; multiple cancers	Yes — RCTs + meta-analysis
8	Vitamin D3	Tier 2	Cancer risk reduction; survival support	Yes — RCTs
9	Omega-3 Fatty Acids	Tier 2	Anti-cachexia; adjunctive chemo support	Yes — RCTs
10	Hyperthermia	Tier 2	Combined with chemo/RT; melanoma, sarcoma	Yes — Multicenter RCTs
11	Melatonin	Tier 2	Chemo adjunct; quality of life	Yes — Multiple RCTs
12	High-dose Vitamin C (IV)	Tier 2	Adjunct to chemo; pharmacologic dosing	Yes — Phase I/II trials
13	Ivermectin	Tier 3	TNBC (Phase I/II trial active); multiple cancers	Limited — Phase I/II ongoing
14	Benzimidazoles (Fenbendazole/Mebendazole/Albendazole)	Tier 3	Multiple cancers; case series + preclinical	Limited — Case series
15	Curcumin (Nanocurcumin)	Tier 3	Anti-inflammatory; adjunct therapy	Limited — Small trials
16	Green Tea (EGCG)	Tier 3	Cancer prevention; epidemiological data	Limited — Observational
17	Berberine	Tier 3	Metabolic targeting; colorectal, breast	Limited — Small trials
18	Disulfiram	Tier 3	GBM; NSCLC; cancer stem cells	Yes — Phase I/II trials
19	Itraconazole	Tier 3	Prostate, lung, basal cell; Hedgehog signalling	Yes — Phase II trials
20	Sildenafil/PDE5 Inhibitors	Tier 3	Chemo sensitisation; immune modulation	Limited — Small trials
21	Glucose Management + Keto Diet + GLP-1	Tier 3	Metabolic oncology; insulin reduction	Limited — Observational
22	Methylene Blue	Tier 3	Photodynamic therapy; ovarian, GBM	Yes — Systematic review (PDT)
23	DMSO	Tier 4	Chemo potentiator; experimental	Anecdotal only
24	Ashwagandha	Tier 4	Immune support; anti-proliferative	Minimal
25	HBOT	Tier 4	Press-Pulse metabolic strategy	Very limited
26	Gerson Therapy	Tier 4	Nutritional/detox; historical only	None robust
27	Hydralazine (GBM)	Tier 4	Glioblastoma; cell studies only	Not yet
28	Stress Reduction, Sleep, Sunshine	Tier 4	Immune support; lifestyle baseline	Indirect

📋 Contents

1. Tier 1: Strong Clinical Evidence (6 interventions)
2. Tier 2: Moderate Clinical Evidence (6 interventions)
3. Tier 3: Emerging / Clinical Series Evidence (10 interventions)
4. Tier 4: Experimental / Preclinical Evidence (6 interventions)
5. Discussion: Where the Field Is Heading
6. Conclusion
7. References

Tier 1: Strong Clinical Evidence

These interventions have the most robust human data — including meta-analyses of randomised controlled trials, approved indications, or landmark trials that have influenced clinical guidelines.

1BCG Immunotherapy Tier 1 · Approved

Cancer type	Non-muscle-invasive bladder cancer (NMIBC)
Evidence	Multiple RCTs; FDA-approved intravesical therapy; standard of care post-TURBT
Dosage	Intravesical instillation — induction + maintenance per urologist protocol
Mechanism	Weakened Mycobacterium bovis stimulates local innate and adaptive immune response against residual cancer cells

Bacillus Calmette-Guérin (BCG) is the gold-standard adjuvant treatment for high-risk NMIBC. It is the most evidence-dense entry on this list — an approved, guideline-recommended immunotherapy that demonstrates the power of immune activation in the bladder microenvironment. Its inclusion here reminds readers that "integrative" can mean evidence-based non-chemotherapy approaches sanctioned by mainstream oncology.

⚠️ BCG therapy is not suitable for all patients (e.g. immunocompromised, active TB). Side effects include bladder irritation, systemic BCG infection (rare). Requires urological supervision.

2Aspirin & COX-2 Inhibitors (Celecoxib) Tier 1 · RCT + Guideline

Cancer types	Colorectal (PIK3CA-mutant), pancreatic, gastric, oesophageal, hepatobiliary
Landmark trial	ALASCCA Trial (NEJM, September 2025) — double-blind RCT across 33 hospitals in Sweden, Denmark, Finland, Norway
Aspirin dosage	75–160 mg/day (post-surgical maintenance) or 325 mg/day for CRC risk reduction
Celecoxib dosage	200–400 mg/day (specialist-guided)
Mechanism	Inhibits COX-1/COX-2 (aspirin) and COX-2 selectively (celecoxib), reducing prostaglandin E2-driven tumour proliferation, angiogenesis, and metastatic adhesion (E-selectin suppression)

The ALASCCA Trial (2025) is the most clinically important recent development in this space. Stage I–III colorectal cancer patients with PIK3CA-pathway mutations — found in over one-third of all CRC — were randomised to 160 mg aspirin or placebo daily for three years post-surgery. The NCCN has since updated guidelines to formally recommend PIK3CA mutation testing in Stage II–III colon cancer and three years of low-dose aspirin for mutation carriers. Aspirin becomes one of the first widely available drugs integrated into precision oncology guidelines.

Separately, a Cardiff University review (BJC 2023) of 118 observational studies in ~1 million cancer patients found daily low-dose aspirin associated with a 21% reduction in all-cause cancer mortality, with particularly strong signals for colorectal (27% risk reduction), gastric (36%), and hepatobiliary (38%) cancers.

For celecoxib, a 2009 landmark study found patients taking COX-2 inhibitors for ≥6 months post-diagnosis were nearly 80% less likely to develop bone metastases in breast cancer. Ben Williams' long-term glioblastoma survival (diagnosed 1995) famously included celecoxib as part of his off-label drug cocktail.

🔗 Read more: ALASCCA Trial Results — Aspirin in PIK3CA-mutant CRC

⚠️ Aspirin increases bleeding risk. Not recommended in patients on anticoagulants without specialist guidance. Celecoxib is contraindicated in patients with severe heart failure.

3Exercise (Aerobic + Resistance Training) Tier 1 · Meta-analyses

Evidence	Multiple systematic reviews and meta-analyses demonstrating improved survival and quality of life across breast, colorectal, prostate, and lung cancers
Aerobic	≥150 min/week moderate-intensity activity
Resistance	2 sessions/week targeting major muscle groups
Mechanism	Reduces chronic inflammation (IL-6, CRP), improves insulin sensitivity, modulates NK-cell and T-cell activity, counters cancer-related fatigue and cachexia

Exercise is the single lifestyle intervention with the strongest and most consistent human evidence across cancer types. Both aerobic exercise and resistance training are recommended by ASCO and major oncology bodies as part of standard supportive care. Studies show 20–40% reduction in cancer-specific mortality in physically active cancer survivors versus sedentary counterparts.

⚠️ Consult your oncologist before beginning exercise programmes during active treatment. Adjust intensity for fatigue, neuropathy, and bone metastases.

4Metformin Tier 1 · Multiple RCTs

Cancer types	Breast, colorectal, pancreatic, endometrial, prostate (data strongest in diabetic patients)
Evidence	Observational meta-analyses show 25–40% reduced cancer mortality in T2DM patients; ADD-IT RCT and other trials ongoing for non-diabetic cancer patients
Dosage	500–1,500 mg daily (start low, titrate for GI tolerance)
Mechanism	Activates AMPK pathway; reduces hepatic glucose output and systemic insulin; inhibits mTOR signalling; reduces IGF-1 axis; possible direct anti-proliferative effects via Complex I inhibition in tumour cells

Metformin's anticancer potential is one of the most extensively studied areas in repurposed oncology pharmacology. Population studies consistently show cancer incidence and mortality reductions in diabetic patients taking metformin versus other glucose-lowering agents. Its safety profile, low cost, and multi-pathway activity make it a cornerstone of metabolic oncology protocols.

⚠️ GI side effects common at initiation. Contraindicated in severe renal impairment (eGFR <30). Long-term use associated with B12 deficiency — supplement with B-complex. Do not combine with berberine without blood glucose monitoring.

5Statins (Atorvastatin / Simvastatin / Pitavastatin) Tier 1 · Meta-analyses

Cancer types	Colorectal, breast, prostate, hepatocellular, oesophageal
Evidence	Multiple meta-analyses; pitavastatin preferred for cancer use due to minimal CYP3A4 interactions; cohort studies across 100,000+ patients
Dosage	Standard cardiovascular dosing; pitavastatin 1–4 mg/day
Mechanism	Inhibits HMG-CoA reductase → disrupts mevalonate pathway → impairs Ras/Rho prenylation → reduces cancer cell proliferation, invasion, and angiogenesis; induces apoptosis via mitochondrial pathway

Meta-analyses across multiple cancer types show statin use associated with 15–35% reductions in cancer-specific mortality. Pitavastatin is increasingly preferred in oncology protocols due to its minimal drug interactions. Statins synergise well with metformin, aspirin, and benzimidazoles in multi-drug repurposing regimens.

🔗 Related: Ivermectin synergy with statins in ovarian cancer (2023 UK/Iraqi study)

6Cimetidine and H2 Blockers Tier 1 · Cochrane Meta-analysis

Cancer types	Colorectal cancer (strongest evidence); limited data for other cancers
Evidence	Cochrane Review 2012 (6 RCTs, 1,229 patients): HR 0.53 (95% CI 0.32–0.87) for overall survival in 5 cimetidine-only trials; 10-year CRC survival 84.6% vs 49.8% in controls (Matsumoto cohort)
Dosage	800 mg/day orally, initiated 2 weeks post-surgery for ~12 months; perioperative use: 400 mg BID for 5 days pre-op, 2 days post-op
Mechanism	Inhibits E-selectin expression on vascular endothelial cells → blocks tumour cell adhesion and liver metastasis; mechanism is class-specific (famotidine and ranitidine do not replicate this effect)

Cimetidine is arguably the most underappreciated repurposed drug in oncology. Its dramatic survival benefit in colorectal cancer — a 10-year survival rate of 84.6% versus 49.8% in the Japanese long-term cohort — has been validated across multiple independent studies. The Cochrane meta-analysis confirms a statistically significant overall survival benefit. Importantly, the benefit appears specific to cimetidine (not other H2 blockers), pointing to mechanisms beyond H2 receptor blockade.

⚠️ Cimetidine raises plasma levels of propranolol; adjust beta-blocker dosing accordingly. Multiple drug interactions — review carefully with your pharmacist.

Tier 2: Moderate Clinical Evidence

These interventions are supported by individual RCTs, systematic reviews of clinical trial data, or prospective cohort studies. The evidence is meaningful but not yet at meta-analysis level, or applies to narrower cancer populations.

7Propranolol (Beta-Blocker) Tier 2 · RCTs + Meta-analysis

Cancer types	Colorectal (perioperative), melanoma, breast, ovarian
Evidence	2025 systematic review of 31 studies (7 RCTs, 4 systematic reviews, 20 meta-analyses); COMPIT trial: perioperative recurrence 12.5% vs 50% (p=0.033)
Dosage	20 mg BID (preoperative taper) → 80 mg on surgery day → 40 mg BID week 1 → 20 mg BID week 2 (COMPIT protocol)
Mechanism	Blocks β-adrenergic receptors on tumour cells → reduces catecholamine-driven proliferation, VEGF secretion, and metastatic spread during surgical stress response

The perioperative window — the days around cancer surgery — represents a period of heightened metastatic risk due to surgical stress hormones. Propranolol blunts this by blocking beta-adrenergic signalling. The COMPIT trial's results (50% vs 12.5% recurrence) are striking, and the 2025 meta-analysis of 31 studies confirms the signal across cancer types. Perioperative propranolol + etodolac represents one of the most compelling low-cost surgical adjuncts in integrative oncology.

⚠️ Contraindicated in asthma, severe bradycardia, uncompensated heart failure. Never stop abruptly — taper under medical supervision.

8Vitamin D3 Tier 2 · RCTs

Cancer types	Breast, colorectal, prostate (prevention and adjunct); cancer mortality reduction
Evidence	VITAL trial (RCT, n=25,871): 25% reduction in cancer mortality after 2 years; multiple RCTs show benefit particularly in deficient populations
Target level	Serum 25(OH)D: 55–90 ng/mL (supplementation titrated to achieve this)
Synergy	Vitamin K2 (MK-7) 100–200 mcg/day + Magnesium 300 mg/day
Mechanism	Binds VDR receptor → modulates cell cycle arrest genes (p21, p27) → induces differentiation, inhibits angiogenesis, modulates immune surveillance via Treg/Th17 balance

⚠️ Patients on warfarin need close monitoring before adding Vitamin K2. Toxicity possible at very high doses — check serum levels before high-dose supplementation.

9Omega-3 Fatty Acids (EPA/DHA) Tier 2 · RCTs

Cancer types	Multiple cancers (anti-cachexia); colorectal, breast, prostate prevention
Evidence	RCTs support anti-cachexia benefits; meta-analyses show ~15% colorectal cancer risk reduction; enhanced chemo efficacy in some trials
Dosage	2,000–4,000 mg EPA + DHA combined daily
Mechanism	EPA/DHA incorporated into cell membranes → alter prostaglandin/leukotriene ratios → reduce tumour-promoting inflammation; inhibit NF-κB; EPA specifically counteracts cancer-related muscle wasting (cachexia)

⚠️ Increased bleeding risk at high doses — use caution with anticoagulants. Choose pharmaceutical-grade, mercury-free supplements.

10Hyperthermia (Thermal Therapy) Tier 2 · Multicenter RCTs

Cancer types	Melanoma (metastatic), soft-tissue sarcoma, cervical cancer, colorectal cancer
Evidence	ESHO multicenter RCT (metastatic melanoma): 2-year local control 46% (hyperthermia + RT) vs 28% (RT alone); 2025 integrative naturopathic study (n=131) showing improved 36-month CRC survival with modulated electrohyperthermia (mEHT)
Types	Local, regional, and whole-body hyperthermia; modulated electrohyperthermia (mEHT); HIFU
Mechanism	Heat (42–45°C) denatures tumour proteins, increases membrane permeability, sensitises hypoxic cells to radiation, enhances chemotherapy uptake, triggers heat-shock protein-mediated immune activation

Thermal therapy schematic. Source: SemanticScholar

🔗 Hyperthermia combined with chemotherapy or radiotherapy consistently outperforms either modality alone. Increasingly available at specialist oncology centres in Europe and Asia.

11Melatonin Tier 2 · Multiple RCTs

Cancer types	Breast, colorectal, lung, prostate; adjunct to chemotherapy
Evidence	Meta-analyses of ~25 RCTs showing improved tumour response rates, 1-year survival, and reduction in chemo side effects when melatonin added to standard treatment
Dosage	20–40 mg at night (oncology doses); standard sleep dose 0.5–5 mg
Mechanism	Scavenges reactive oxygen species; induces apoptosis via mitochondrial pathway; modulates immune function (NK cell activity); anti-angiogenic; epigenetic effects on tumour suppressor gene expression

⚠️ High-dose melatonin may cause vivid dreams and daytime somnolence. Start low. Potential interaction with immunosuppressants.

12High-Dose Intravenous Vitamin C Tier 2 · Phase I/II Trials

Cancer types	Multiple cancers; most evidence as chemo adjunct in pancreatic, ovarian, lung cancers
Evidence	2026 major review (150+ studies): pharmacologic IV dosing achieves 20–30 mM serum levels with tumour-selective pro-oxidant effects. 2022 systematic review: improved cancer survival with vitamins C and E. Phase I/II trials confirm safety and signal efficacy
IV Dosage	1.5 g/kg/day, 2–3× weekly (Fan et al., 2023); oral Vitamin C does not achieve therapeutic cancer doses
Mechanism	At pharmacologic concentrations, ascorbate acts as a pro-oxidant → generates H₂O₂ selectively in tumour cells (low catalase activity) → oxidative tumour cell death; spares normal cells

The key distinction from earlier negative studies (Mayo Clinic 1985): oral vitamin C does not achieve pharmacologic serum levels. Intravenous administration is essential for anticancer effects. The aspirin–vitamin C combination shows synergistic activity in animal models (73% lifespan extension vs untreated controls; 46% tumour volume reduction).

⚠️ IV Vitamin C is contraindicated in patients with G6PD deficiency (risk of haemolysis). Requires specialist administration and monitoring.

Tier 3: Emerging Evidence (Clinical Series / Observational)

These interventions have meaningful human data — case series, observational studies, small clinical trials, or Phase I/II data — combined with strong preclinical rationale. They lack large RCT confirmation but are being actively investigated.

13Ivermectin Tier 3 · Phase I/II Trial Active

Cancer types	Triple-negative breast cancer (active trial); leukemia, colorectal, gastric, lung, prostate, ovarian (case series)
Best human evidence	De Castro 2020 (refractory AML, paediatric, 1 mg/kg/day); Ishiguro 2022 (12 mg BID); NCT05318469 Phase I/II TNBC trial (Cedars-Sinai, 2025 ASCO results)
Case series	700+ compiled case reports including Stage 4 NED cases — see Ivermectin Cancer Case Reports Compilation
Research funding	$60 million Florida Cancer Innovation Fund; multiple Phase I/II trials registered
Mechanism	T-cell activation and tumour infiltration; synergy with immune checkpoint blockade; PAK1 inhibition; Wnt/β-catenin pathway suppression; P-glycoprotein inhibition; mitochondrial membrane disruption in cancer cells

Ivermectin dosage for cancer treatment — dosing differs significantly from antiparasitic use

Ivermectin occupies a unique position: it has 400+ publications (mostly preclinical), a growing case series dataset, active Phase I/II trials, and $60 million in dedicated research funding. The 2025 ASCO results from the Cedars-Sinai TNBC trial (NCT05318469) mark the first formal clinical efficacy data in a solid tumour.

⚠️ Standard antiparasitic dosing is inadequate for oncology use. Ivermectin does not cross the blood-brain barrier — likely ineffective for primary brain tumours. Dosing should be guided by an integrative oncologist familiar with current cancer protocols. See: Dr Makis Protocol (2026)

14Benzimidazoles: Fenbendazole / Mebendazole / Albendazole Tier 3 · Case Series + Preclinical

Cancer types	Multiple cancers (lung, colorectal, prostate, ovarian, glioma — case series); glioma (mebendazole clinical studies)
Best human evidence	Mebendazole Phase I/II trials in glioma and colorectal cancer; fenbendazole and ivermectin case series across 700+ patients; Joe Tippens Protocol (small-cell lung cancer NED, 8+ years)
Dosage	Mebendazole: 100–200 mg/day; Fenbendazole: 222 mg 3×/week (Tippens) to daily dosing; Albendazole: 400 mg BID with food
Mechanism	Disrupts β-tubulin polymerisation → inhibits cancer cell mitosis (similar to taxanes/vinca alkaloids); inhibits glucose uptake (GLUT-1); blocks STAT3 signalling; targets cancer stem cells; anti-angiogenic via VEGFR2 inhibition

Mebendazole has the strongest human data of the three, with formal Phase II trials in glioma showing it crosses the blood-brain barrier. Fenbendazole achieved international attention via Joe Tippens' survival from metastatic SCLC. Both are affordable and widely available. Of note: fenbendazole is a veterinary drug without human approval; mebendazole is the human-approved equivalent and is preferred for human use.

🔗 Read: Fenbendazole vs Mebendazole for Cancer: What Is the Difference?

15Disulfiram + Copper Tier 3 · Phase I/II Trials

Cancer types	Glioblastoma, NSCLC, TNBC; APC-mutant colorectal cancer (precision oncology signal)
Evidence	Phase I/II clinical trials completed; population-level data showing cancer patients who continued disulfiram had better survival than those who stopped (Danish cohort study)
Dosage	80 mg TID or 250 mg once daily + Copper 2 mg TID
Mechanism	Disulfiram-copper complex → inhibits proteasome (26S) and NF-κB pathway → increases ROS in cancer cells → apoptosis; inhibits ALDH → targets cancer stem cells; reverses chemo-resistance

⚠️ Patients must strictly avoid alcohol — severe cardiovascular reactions can occur. Not suitable for patients with hepatic impairment.

🔗 Related: Disulfiram in APC-Mutated CRC: Precision Oncology Application

16Itraconazole Tier 3 · Phase II Trials

Cancer types	Prostate cancer, NSCLC, basal cell carcinoma, medulloblastoma
Evidence	Phase II trials in prostate cancer (PSA response), basal cell carcinoma (Hedgehog inhibition); retrospective cohort data in NSCLC
Dosage	100–400 mg/day (higher doses require LFT monitoring for hepatotoxicity)
Mechanism	Inhibits Hedgehog (Hh) signalling pathway; blocks VEGFR2 and angiogenesis; reverses P-glycoprotein-mediated chemoresistance; inhibits mTOR and Wnt/β-catenin pathways

⚠️ Significant drug interactions including with statins, rituxumab, and cimetidine. Hepatotoxicity risk at high doses — monitor LFTs regularly.

17Curcumin (Nanocurcumin) Tier 3 · Small Clinical Trials

Cancer types	Colorectal, pancreatic, breast, prostate; multiple cancers (adjunct)
Evidence	Multiple Phase I/II trials; bioavailability limitation addressed by nanoformulations; 500+ preclinical studies
Dosage	500–1,000 mg nanocurcumin daily (standard curcumin poorly absorbed)
Mechanism	Inhibits NF-κB, STAT3, AP-1, and COX-2 → anti-inflammatory; induces apoptosis; inhibits tumour cell invasion and angiogenesis; epigenetic modulation (DNMT inhibition)

⚠️ Curcumin interacts with anticoagulants (warfarin, clopidogrel), some antibiotics, and antidepressants. Use nanocurcumin or phospholipid complexes for adequate bioavailability.

18Green Tea (EGCG) Tier 3 · Epidemiological + Mechanistic

Cancer types	Breast, prostate, colorectal, gastric, lung (prevention signals in epidemiological data)
Evidence	Epidemiological studies from Japan show 30–40% lower cancer incidence in high green tea consumers; Phase II trial data in prostate cancer (CLL); mechanistic clinical data on VEGF and IGF-1 suppression
Dosage	3–5 cups green tea daily or 500–1,000 mg standardised EGCG extract
Mechanism	EGCG inhibits angiogenesis (VEGF/VEGFR2), induces apoptosis, inhibits tumour cell migration, modulates Wnt/β-catenin and PI3K/Akt pathways, epigenetic demethylation of tumour suppressor genes

⚠️ High-dose green tea extract may be hepatotoxic in individuals with underlying liver conditions — use with caution and monitor LFTs.

19Berberine Tier 3 · Small Clinical Trials

Cancer types	Colorectal, breast, cervical, hepatocellular; metabolic cancer synergy
Evidence	Phase II data in colorectal adenoma prevention; clinical trials ongoing; strongest evidence as metformin alternative/synergist in metabolic cancer protocols
Dosage	500 mg 2–3× daily with meals
Mechanism	Activates AMPK (similar to metformin); inhibits mTOR; induces cell cycle arrest and apoptosis; anti-angiogenic; suppresses pSTAT3 signalling; modulates gut microbiome with downstream anti-tumour effects

⚠️ Absolute contraindication with cyclosporine (raises levels dangerously). Monitor blood glucose when combining with metformin. May alter metabolism of warfarin, tacrolimus, sedatives, and losartan.

20PDE5 Inhibitors (Sildenafil / Tadalafil / Vardenafil) Tier 3 · Phase I/II Trials

Cancer types	Melanoma, multiple myeloma, head and neck cancer, colorectal (investigational)
Evidence	Phase I/II trials showing PDE5i reverse tumour immune evasion; preclinical synergy with chemotherapy; sildenafil + docetaxel in prostate cancer trial data
Dosage	Sildenafil 20 mg/day or tadalafil 5 mg/day (cancer protocols; differs from ED dosing)
Mechanism	cGMP elevation → promotes autophagy and apoptosis in tumour cells; suppresses myeloid-derived suppressor cells (MDSCs) → enhances T-cell mediated tumour killing; synergy with PD-1/PD-L1 checkpoint inhibitors

⚠️ Absolutely contraindicated with nitrates (risk of severe hypotension). Caution in patients with history of NAION. Serious cardiovascular side effects possible.

21Glucose Management, Ketogenic Diet & GLP-1 Agonists Tier 3 · Observational + Metabolic Oncology

Cancer types	Multiple cancers (Warburg effect-dependent tumours); obesity-related cancers (GLP-1 data)
Evidence	2025 ASCO data: GLP-1 receptor agonists modestly reduce risk of 14 obesity-related cancers in diabetics; observational data for ketogenic diet in glioma and NSCLC; CGM studies showing post-meal glucose as tumour growth proxy
Approach	Limit carbohydrates <25 g/day (strict keto); post-meal glucose target <120 mg/dL via CGM; GKI (Glucose-Ketone Index) as metabolic monitoring tool
Mechanism	Reduces circulating glucose and insulin → starves Warburg-dependent tumour cells; ketone bodies cannot be efficiently metabolised by most cancer cells; reduced IGF-1 signalling; synergy with fasting-mimicking approaches

🔗 Related: FLCCC Fasting and Healthy Eating Guide

22Methylene Blue Tier 3 · Systematic Review (PDT) + In Vivo

Cancer types	Ovarian (platinum-resistant), colorectal, melanoma, glioblastoma
Evidence	Lim 2023 systematic review (PDT efficacy in colorectal, carcinoma, melanoma); Da Veiga Moreira 2024 (in vivo ovarian tumour restraint); Makis 2025 (post-surgical breast cavity clearance; GBM + TMZ synergy)
Dosage	Not yet standardised for oncology use; PDT protocols are centre-specific
Mechanism	Mitochondrial Complex IV enhancer (electron carrier); photosensitiser for PDT → generates singlet oxygen to destroy tumour cells; inhibits mTOR; reduces mitochondrial ROS in normal cells while increasing it in cancer cells

🔗 Read: Methylene Blue for Cancer: Mechanisms and Clinical Implications

Tier 4: Experimental / Primarily Preclinical

These interventions lack robust human clinical trial data. Some have strong biological rationale and emerging case report signals. They are listed here for completeness and to reflect current integrative oncology discussion — not as recommended treatments.

23DMSO (Dimethyl Sulfoxide) Tier 4 · Preclinical + Anecdotal

Evidence status	In vitro studies (bladder, breast, leukemia, prostate, ovarian, lung); no peer-reviewed human cancer trials; anecdotal case reports only
Proposed uses	Chemo potentiator (carrier/solvent enhancing drug penetration); direct anti-proliferative; immune modulation; combined with hematoxylin (experimental)
Mechanism (proposed)	Induces cancer cell differentiation and apoptosis; increases cell membrane permeability → enhances drug delivery; stimulates immune recognition of tumour cells

Dr William Makis (April 2026) summarised the current status clearly: "DMSO's use in cancer is not documented. In comparison to DMSO, Ivermectin has 400+ publications, several human clinical trials coming, $60 million research backing... Would I support DMSO research in cancer? Absolutely." This captures where DMSO sits — promising biology, zero human trial evidence, warranting investigation rather than clinical use.

🔗 Read: DMSO and Cancer: The Overlooked Therapy (OneDayMD Substack)

24Ashwagandha (Withania somnifera) Tier 4 · Preclinical

Evidence status	Preclinical studies (in vitro and animal); very limited small human trials (stress reduction, not oncology endpoints)
Proposed uses	Adjunct to chemotherapy (reduce toxicity, enhance cisplatin efficacy); immunostimulation; anti-proliferative in breast, cervical, colon cancer cells
Dosage	300–500 mg standardised extract (KSM-66 or Sensoril) twice daily
Mechanism (preclinical)	Withanolides modulate NF-κB, STAT3, Notch/AKT/mTOR; induce apoptosis; reduce tumour cell migration; Withaferin A shows strongest in vitro anticancer activity

⚠️ May affect thyroid hormone levels — monitor if thyroid conditions present. Potential drug interactions with immunosuppressants and thyroid medications.

25Hyperbaric Oxygen Therapy (HBOT) Tier 4 · Theoretical + Very Limited Clinical

Evidence status	Strong theoretical basis (Otto Warburg); very limited human cancer outcome trials; established for radiation injury, wound healing (approved uses)
Press-Pulse role	Part of metabolic cancer strategy: HBOT as "press" (chronic metabolic stress on tumours) combined with glucose restriction and ketogenic diet
Mechanism (proposed)	Delivers supraphysiologic oxygen → hostile environment for hypoxic cancer cells that depend on anaerobic glycolysis; reverses tumour-induced immunosuppression; sensitises cancer cells to radiation

🔗 Read: HBOT in Cancer: Which Tumours Benefit Most? (2026)

26Gerson Therapy Tier 4 · Historical / No Robust Clinical Trials

Evidence status	No peer-reviewed RCTs; historical case reports; observational data only; not endorsed by any major oncology body
Protocol elements	Organic plant-based diet; 13 glasses fresh juice/day; coffee enemas (up to 5×/day); beef liver; supplements (Lugol's, pancreatic enzymes, potassium, thyroid, B12)
Rationale	Metabolic restoration theory: rebalances sodium/potassium homeostasis; depletes tumour environment of glucose while flooding body with micronutrients; coffee enemas stimulate bile flow and liver detoxification

The Gerson Therapy occupies a complex position: historically significant, patient communities report subjective benefits, but it lacks any rigorous clinical evidence and its intensive nature makes adherence difficult. Coffee enemas carry real risks including electrolyte disturbances and rare fatalities. If considered, it should be supervised by an experienced Gerson-trained practitioner.

27Hydralazine (Glioblastoma) Tier 4 · Cell Studies Only

Cancer type	Glioblastoma (experimental; cell lines only)
Evidence status	In vitro cell studies showing growth arrest; no animal studies published; no human trials
Mechanism (proposed)	Blocks oxygen-sensing enzyme EGLN1 (PHD2) → suppresses HIF-1α activation in cancer cells → prevents tumour survival in hypoxic conditions → growth arrest (senescence) rather than cell death

The press release from Memorial Sloan Kettering emphasises this is a starting point for drug repurposing, not a clinical treatment. As a blood-pressure drug already FDA-approved, it could enter trials faster than novel compounds — but human evidence is entirely absent at this stage.

28Stress Reduction, Sleep & Sunshine Tier 4 · Lifestyle Foundation

Evidence status	Strong indirect evidence linking chronic stress, sleep deprivation, and low vitamin D to cancer incidence and progression; no direct RCTs testing stress reduction as cancer treatment
Sleep target	7–9 hours restorative sleep; sleep disruption suppresses melatonin and NK cell activity
Stress techniques	Meditation, deep breathing, mindfulness, nature exposure — 15+ minutes outdoors daily
Mechanism	Chronic cortisol elevation → immunosuppression → reduced tumour surveillance; sleep deprivation → reduced melatonin → loss of apoptotic signalling; sunshine → vitamin D synthesis → VDR-mediated cancer suppression pathways

Although ranked Tier 4 due to lack of direct RCT evidence for oncology outcomes, these three lifestyle factors represent the essential non-negotiable foundation of any integrative cancer protocol. Their indirect evidence is compelling and their risk profile is zero. They should be considered prerequisites, not additions.

Discussion: Where the Field Is Heading

Credit: Independent Medical Alliance

Several clear themes emerge from this evidence-ranked review:

The Tier 1 story is already compelling. Exercise, aspirin (for PIK3CA-mutant CRC), metformin, statins, and cimetidine are supported by meta-analyses and guideline updates. These are not "fringe" therapies — they are data-supported, low-cost interventions that most oncology teams do not actively prescribe. The ALASCCA trial has already moved aspirin into NCCN guidelines. Cimetidine's Cochrane HR of 0.53 in CRC is more impressive than many approved drugs.

The perioperative window is critically underutilised. Propranolol and cimetidine both show their strongest signals in the perioperative context — the days around cancer surgery when immune suppression and stress-hormone surges create metastatic opportunity. Addressing this pharmacologically is low-risk and supported by trial data.

Repurposed antiparasitics are advancing. Ivermectin and benzimidazoles are moving from Tier 3 towards Tier 2. The $60 million Florida Cancer Innovation Fund, the Cedars-Sinai TNBC trial, and growing Phase I/II pipeline mark a genuine inflection point. Within two to three years, RCT data will either confirm or challenge the case-series signals.

Metabolic oncology is maturing. Metformin, statins, berberine, glucose restriction, and GLP-1 agonists are converging around a coherent framework: disrupt cancer cell metabolic dependencies while preserving normal cell function. The 2025 ASCO GLP-1 cancer data and the insulin/cancer evidence base are strengthening this approach.

DMSO and Tier 4 interventions warrant monitored investigation, not dismissal. As Dr Makis noted, the biology is interesting and the compounds are available. What is needed is documentation — peer-reviewed case series, then formal trials. The same trajectory that took ivermectin from anecdote to $60 million in funded research is available to DMSO if clinicians document and publish their cases.

Conclusion

The best version of cancer care is not one in which patients must choose between "standard medicine" and "alternative care." It is one that coordinates evidence-based treatment with patient-centric, thoughtful, safe supportive strategies — organised by the quality of available evidence.

This review presents a framework for that coordination. Start with Tier 1: aspirin for PIK3CA-mutant CRC, exercise, metformin, statins, cimetidine for colorectal cancer, and BCG for bladder cancer. These are evidence-backed, low-cost, and underutilised. Add Tier 2 interventions — propranolol, vitamin D, omega-3, IV vitamin C, hyperthermia, melatonin — guided by cancer type and patient context. Consider Tier 3 repurposed drugs (ivermectin, benzimidazoles, disulfiram, itraconazole) under physician supervision, with clear biomarker monitoring. Treat Tier 4 interventions as experimental — potentially valuable, currently unproven in humans.

To find integrative oncologists who can guide this process, see our Integrative Oncologist Directory. For comprehensive protocol guidance, see Cancer Care 2nd Edition (Dr Paul Marik, FLCCC).

Key References & Further Reading

1. ALASCCA Trial — Aspirin in PIK3CA-mutant CRC. NEJM, September 2025. [Summary]
2. Cochrane Review — Cimetidine adjuvant therapy in colorectal cancer. 2012 (6 RCTs, 1,229 patients).
3. ESHO Multicenter Trial — Hyperthermia + radiotherapy in metastatic melanoma. [Source]
4. COMPIT Trial — Perioperative propranolol + etodolac in CRC. Eur J Surg Oncol. 2023.
5. Propranolol systematic review (31 studies, 7 RCTs). PMC. 2025. [Source]
6. NCT05318469 — Ivermectin + Balstilimab in metastatic TNBC. Cedars-Sinai. 2025 ASCO results. [Trial]
7. De Castro et al. Ivermectin in refractory paediatric AML. Anticancer Res. 2020. [PubMed]
8. Ishiguro et al. Ivermectin case series. 2022. [PubMed]
9. Cardiff University — Aspirin and cancer mortality. Br J Cancer. 2023. [Source]
10. Aspirin and digestive tract cancers meta-analysis. Annals of Oncology. 2020.
11. High-dose vitamin C review (150+ studies). J Pharmacol Sci. 2026. [Source]
12. Fan et al. IV Vitamin C dosing (1.5g/kg/day). 2023.
13. Lim. MB-mediated PDT — systematic review. 2023. [PMC]
14. Da Veiga Moreira et al. Methylene blue in ovarian cancer. 2024. [PMC]
15. Matsumoto et al. Cimetidine 10-year survival in CRC. Br J Cancer. 2002.
16. Marik PE. Cancer Care: 2nd Edition. FLCCC/IMA Health. [imahealth.org]
17. Integrative naturopathic treatment + mEHT in CRC (n=131). Integrative Medicine and Health. 2025.
18. Nature — Drug repurposing in cancer. 2024. [Source]
19. Top 10 Cancer Fighting Supplements — Cancer Advisor
20. Fenbendazole vs Mebendazole for Cancer
21. Enhanced Ivermectin + Mebendazole 16-Week Protocol (OneDayMD Substack)